Xencor Inc. (NASDAQ:XNCR) traded down 3.7% on Thursday . The stock traded as low as $18.15 and last traded at $18.15, with a volume of 113,722 shares. The stock had previously closed at $18.84.

Several equities research analysts have weighed in on the company. Zacks Investment Research raised Xencor from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Tuesday. Canaccord Genuity reaffirmed a “buy” rating on shares of Xencor in a report on Tuesday, June 28th. Leerink Swann reaffirmed an “outperform” rating and set a $18.00 target price on shares of Xencor in a report on Wednesday, June 29th. Wedbush reaffirmed an “outperform” rating and set a $27.00 target price on shares of Xencor in a report on Tuesday, June 28th. Finally, TheStreet raised Xencor from a “sell” rating to a “hold” rating in a report on Monday, April 25th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $23.29.

The company’s market capitalization is $755.41 million. The firm’s 50-day moving average is $14.68 and its 200 day moving average is $13.04.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. The business earned $7.30 million during the quarter, compared to analysts’ expectations of $3.50 million. On average, equities analysts predict that Xencor Inc. will post ($0.78) EPS for the current year.

In other news, CEO Bassil I. Dahiyat sold 45,886 shares of the stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $13.00, for a total value of $596,518.00. Following the transaction, the chief executive officer now owns 358,186 shares in the company, valued at approximately $4,656,418. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

An institutional investor recently raised its position in Xencor stock. Geneva Advisors LLC raised its position in shares of Xencor Inc. (NASDAQ:XNCR) by 8.0% during the fourth quarter, Holdings Channel reports. The fund owned 76,196 shares of the biopharmaceutical company’s stock after buying an additional 5,641 shares during the period. Geneva Advisors LLC owned 0.19% of Xencor worth $1,114,000 at the end of the most recent quarter.

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.